CagriSema, the cagrilintide and semaglutide combination, has been filed for FDA review, but filing is not approval
**BPC-157, a synthetic gastric pentadecapeptide studied primarily in animal models for tissue repair, gut healing, and anti-inflammatory effects, remains unapproved by the FDA as a finished drug with only limited small-scale human data available.** It was placed in Category 2 in 2023 due to concerns over immunogenicity, peptide impurities, and insufficient safety information for compounding under Section 503A
This work provided the pharmacological rationale for HGH Fragment as a selective lipolytic research tool
Research in rodent models has consistently demonstrated that supplement with 25(OH)D3 leads to increased expression of NGF and BDNF in central nervous system tissues, highlighting the potential neurotrophic effects of VD metabolites [101]
As a promising source of pharmacological compounds to treat Poly Cystic Ovary Syndrome (PCOS): A review
Taking massive "megadoses" of standard capsules often just results in expensive waste
